FATE (Fate Therapeutics Inc) Cumulative Company Assets

Official company branding of Fate Therapeutics Inc (FATE)

The business model of Fate Therapeutics, Inc. (FATE) faces significant threats due to high production costs and the potential for new drug trial failures. Nevertheless, Fate Therapeutics, Inc. (FATE) is considered a pioneer in iPSC therapy, which secures a vote of confidence from experts. While the company handles development in-house, testing is outsourced to contractors. This chart illustrates that total assets amount to 315.87.

Fate Therapeutics Inc (FATE) Aggregate Company Assets: for the period 07/04/2022 - 10/30/2026

Financial and market metric breakdowns for Fate Therapeutics Corp (FATE)

- stock value and consensus price forecast:
Market Price fatetherapeutics.com|FATE - Analyst Consensus Forecast
- business market valuation indicators:
Market Valuation Fate Pharma|FATE - Enterprise Value
- company book value details:
Book Value per Share Fate Therapeutics|FATE - Company Book Value|Capitalization to Book Value Ratio fatetherapeutics.com|FATE - Company Total Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio Fate Therapeutics, Inc.|FATE - Long-Term Debt to Capital|Current Liabilities to Capital Fate Pharma|FATE - Company Debts|Debt to Net Assets Ratio Fate Pharma|FATE - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Fate Therapeutics|Quick Liquidity Indicator fatetherapeutics.com
- earnings and market multiples details:
FATE - Net Income
Basic company analysis:fatetherapeutics.com (FATE)
Core merchandise of Fate Therapeutics

Fate Therapeutics, Inc. (FATE) is investing significant resources into retaining its R&D core and recruiting bioinformaticians to advance cell therapy. The dynamics of these expenditures are inversely reflected in the calculation of total assets via return on assets (ROA), filtering out market noise. This metric measures the actual volume of controlled assets, allowing for the separation of fundamental value from exchange volatility. Analyzing the forecast for assets and resources helps assess business resilience during a prolonged downturn in demand.

Key competitors

Company Assets beigene.com (ONC)|HALO (Halozyme) - Company Total Assets|Cumulative Company Assets Revolution Medicines Inc (RVMD)|Company Total Assets AAPG|Company Total Assets CG Oncology Therapeutics (CGON)|Aggregate Company Assets UroGen Pharma Ltd. URGN|BCAX: Total Business Assets|Personalis - Company Total Assets|Erasca Inc (ERAS) - Cumulative Company Assets|DCTH: Company Total Assets|Company Assets Y-mAbs Corp (YMAB)|Aggregate Company Assets Aura Biosciences, Inc.|CADL: Aggregate Asset Value|Cumulative Company Assets ARAY (Accuray)|SLS (sellaslifesciences.com) - Aggregate Asset Value|Company Total Assets ACTU (Actuate Therapeutics, Inc)|CTOR - Cumulative Company Assets|HURA: Cumulative Company Assets|TARA - Company Total Assets|aadibio.com (WHWK) - Aggregate Company Assets|TScan Therapeutics, Inc. - Aggregate Asset Value|CSBR (Champions Oncology Inc) - Company Total Assets|Company Assets XBiotech USA XBIT|Company Total Assets CVM|OSTX: Total Asset Value of Company|Company Total Assets RADX (Radiopharm Theranostics)|Company Total Assets Artiva Biotherapeutics Inc. ARTV|ANL: Cumulative Company Assets|Veru Corporation - Aggregate Business Assets|TPST: Company Total Assets|Company Assets Xilio Therapeutics (XLO)|Cumulative Company Assets RENB|MURA: Aggregate Asset Value|Cumulative Company Assets KAPA (Kairos Pharma Ltd)|Aggregate Business Assets OKUR|Company Total Assets GDTC (CytoMed Therapeutics Limited)|Aggregate Asset Value CRIS|Apollomics Corp - Company Total Assets|Company Assets Tharimmune Inc|advanbiomed.com (ADVB) - Aggregate Company Assets|Genprex Inc - Aggregate Asset Value|CLDI (Calidi Biotherapeutics Inc.) - Company Total Assets|Company Total Assets sunshinebiopharma.com|Aggregate Company Assets Xenetic Biosciences (XBIO)|SLRX: Total Asset Value of Company|Company Total Assets PPBT (Purple Biotech Corp)|American Oncology Network Inc (AONC) - Company Assets|BGNE: Cumulative Company Assets|CKPT - Company Total Assets|ELEV (Elevation Oncology) - Cumulative Company Assets|ICAD: Aggregate Business Assets|IKNA (Ikena Oncology Inc.) - Company Total Assets|Notable Labs Corp (NTBL) - Company Total Asset Base|Company Total Assets VIRX|Cumulative Company Assets morphosys.com MOR|Aggregate Company Assets NAYA Biosciences Inc. NAYA|Company Total Asset Base Ascentage Pharma Group International (AAPGV)